Articles with public access mandates - Jun LuoLearn more
Not available anywhere: 5
Androgen receptor modulation optimized for response—splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7 …
ME Taplin, ES Antonarakis, KJ Ferrante, K Horgan, B Blumenstein, ...
European urology 76 (6), 843-851, 2019
Mandates: US Department of Defense, US National Institutes of Health
Discovery of a small-molecule inhibitor targeting the androgen receptor N-terminal domain for castration-resistant prostate cancer
Q Yi, W Liu, JH Seo, J Su, MA Alaoui-Jamali, J Luo, R Lin, JH Wu
Molecular cancer therapeutics 22 (5), 570-582, 2023
Mandates: Canadian Institutes of Health Research
Integrative analysis of AR‐mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression
Y Cheng, D Wang, J Jiang, W Huang, D Li, J Luo, W Gu, W Mo, C Wang, ...
The Prostate 80 (8), 640-652, 2020
Mandates: National Natural Science Foundation of China
Specific detection of prostate cancer cells in urine by RNA in situ hybridization
JN Eskra, D Rabizadeh, J Zhang, WB Isaacs, J Luo, CP Pavlovich
The Journal of urology 206 (1), 37-43, 2021
Mandates: US National Institutes of Health
The expression signature of androgen receptor splice variants and their distinctive transcriptional activities in castration-resistant prostate cancer
SR Plymate, J Luo
Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and …, 2013
Mandates: US National Institutes of Health
Available somewhere: 99
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ...
New England Journal of Medicine 371 (11), 1028-1038, 2014
Mandates: US National Institutes of Health
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer
R Hu, TA Dunn, S Wei, S Isharwal, RW Veltri, E Humphreys, M Han, ...
Cancer research 69 (1), 16-22, 2009
Mandates: US National Institutes of Health
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
W Liu, S Laitinen, S Khan, M Vihinen, J Kowalski, G Yu, L Chen, ...
Nature medicine 15 (5), 559-565, 2009
Mandates: US National Institutes of Health
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ...
JAMA oncology 1 (5), 582-591, 2015
Mandates: US National Institutes of Health
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer
R Hu, C Lu, EA Mostaghel, S Yegnasubramanian, M Gurel, C Tannahill, ...
Cancer research 72 (14), 3457-3462, 2012
Mandates: US National Institutes of Health
Breaking the scaling relationship via thermally stable Pt/Cu single atom alloys for catalytic dehydrogenation
G Sun, ZJ Zhao, R Mu, S Zha, L Li, S Chen, K Zang, J Luo, Z Li, SC Purdy, ...
Nature Communications 9 (1), 4454, 2018
Mandates: US National Science Foundation, US Department of Energy, National Natural …
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
B Gurel, T Iwata, CM Koh, RB Jenkins, F Lan, C Van Dang, JL Hicks, ...
Modern pathology 21 (9), 1156-1167, 2008
Mandates: US National Institutes of Health
miR-21: an androgen receptor–regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth
J Ribas, X Ni, M Haffner, EA Wentzel, AH Salmasi, WH Chowdhury, ...
Cancer research 69 (18), 7165-7169, 2009
Mandates: US National Institutes of Health
Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with …
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ...
Journal of Clinical Oncology 35 (19), 2149-2156, 2017
Mandates: US Department of Defense, US National Institutes of Health
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ...
The Journal of clinical investigation 129 (1), 192-208, 2019
Mandates: US Department of Defense, US National Institutes of Health, US Department of …
Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death
A Apostolou, Y Shen, Y Liang, J Luo, S Fang
Experimental cell research 314 (13), 2454-2467, 2008
Mandates: US National Institutes of Health
Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study
AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ...
Journal of Clinical Oncology 37 (13), 1120-1129, 2019
Mandates: US Department of Defense, US National Institutes of Health
The mutational landscape of prostate cancer
CE Barbieri, CH Bangma, A Bjartell, JWF Catto, Z Culig, H Grönberg, ...
European urology 64 (4), 567-576, 2013
Mandates: US National Institutes of Health
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases
MJ Aryee, W Liu, JC Engelmann, P Nuhn, M Gurel, MC Haffner, D Esopi, ...
Science translational medicine 5 (169), 169ra10-169ra10, 2013
Mandates: US National Institutes of Health, German Research Foundation
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study
MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ...
Science translational medicine 7 (269), 269ra2-269ra2, 2015
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program